Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Synchron | 2025 | Series D | $200.0M | Brooklyn |
| Elephas | 2025 | Series Unknown | $40.0M | Madison |
| Sonoma Biotherapeutics | 2025 | Grant | $300K | South San Francisco |
| Pelage Pharmaceuticals | 2025 | Series B | $120.0M | Los Angeles |
| Kardigan | 2025 | Series B | $254.0M | South San Francisco |
| Volastra Therapeutics | 2025 | Series A | $30.1M | New York |
| Ollin Biosciences | 2025 | Series A | $100.0M | Austin |
| Maze Therapeutics | 2025 | Post Ipo Equity | $150.0M | South San Francisco |
| Rapport Therapeutics | 2025 | Post Ipo Equity | $250.0M | Boston |
| Prime Medicine | 2025 | Post Ipo Equity | $5.0M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Synchron | Series D | $200.0M | Brooklyn, United States |
| 52 | Elephas | Series Unknown | $40.0M | Madison, United States |
| 53 | Sonoma Biotherapeutics | Grant | $300K | South San Francisco, United States |
| 54 | Pelage Pharmaceuticals | Series B | $120.0M | Los Angeles, United States |
| 55 | Kardigan | Series B | $254.0M | South San Francisco, United States |
| 56 | Volastra Therapeutics | Series A | $30.1M | New York, United States |
| 57 | Ollin Biosciences | Series A | $100.0M | Austin, United States |
| 58 | Maze Therapeutics | Post Ipo Equity | $150.0M | South San Francisco, United States |
| 59 | Rapport Therapeutics | Post Ipo Equity | $250.0M | Boston, United States |
| 60 | Prime Medicine | Post Ipo Equity | $5.0M | Cambridge, United States |
Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.
Elephas harnesses latest advances in cancer biology, multimodal microscopy, and artificial intelligence to empower clinical decision-making.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Pelage Pharma is a regenerative medicine biotechnology company developing treatments for hair loss.
Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Ollin Biosciences operates as a clinical-stage biopharmaceutical company.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
AIRNA develops RNA editing technologies to create medicines for various diseases.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Homeward is focused on improving access to high-quality, affordable primary and specialty care in rural communities.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
Generate Biomedicines is a biotech company that combines biology, machine learning, and biological engineering to create biomedicines.
Akamis Bio is a clinical-stage oncology company.
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
ARCH Venture Partners has invested in 156 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Pharmaceutical. The firm invests across 19 different industry categories.
Among tracked funding rounds, Kardigan received $254.0M in a Series B round. ARCH Venture Partners's total known invested capital is $14.3B.
ARCH Venture Partners's average investment size is $119.8M across its portfolio of 156 companies.
Recent ARCH Venture Partners portfolio additions include Synchron, Elephas, Sonoma Biotherapeutics, Pelage Pharmaceuticals, Kardigan. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors